Diagnostic utility of positron emission tomography in the evaluation of gliomas;Utilidad diagnóstica de la tomografía de emisión de positrones en la evaluación de los gliomas

Clinical and Translational Oncology

Volumn 2, Issue 1, 2000, Pages 3-11

  Cenzano, Cristina Gámez ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

C 11 MET; F 18 FDG; Gliomas; Positron emission tomography

Indexed keywords

EID: 84873647430     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Di Chiro G, De la Paz RL, Brooks RA, Sokoloff L, Korn-blith PL, Smith BH et al. Glucose utilization of cerebral gliomas measured by [18F]- fluorodeoxyglucose and positron emission tomography. Neurology 1982; 32: 1323-1329.
2. Phelps ME, Mazziotta JC, Schelbert HR, editores. Positron emission tomography and autoradiography: principal applications for the brain and the heart. Nueva York: Raven Press, 1986.
3. Wahl RL. Clinical oncology update: the emerging role of PET: part I. En: De Vita VT, Hellman S, Rosenberg SA, editores. Filadelfia: Lippincott-Raven, 1997; Vol 11(1): 1-18.
4. Wahl RL. Clinical oncology update: the emerging role of PET: part II. En: De Vita VT, Hellman S, Rosenberg SA, editores. Filadelfia: Lippincott-Raven, 1997; Vol 11(2): 1-24.
5. Richter JA, Martí JM. PET. Tomografía molecular. Fun-damentos y aplicaciones. Madrid: Eseuve, 1993.
6. Valk PE. Sense and sensitivity: issues in technology assessment [editorial]. J Nucl Med 1996; 37: 1436-1437.
7. Beany RP. Positron emission tomography in the study of human tumors. Sem Nucl Med 1984; 14: 324-341.
8. Mineura K, Yasuda T, Kowada M, Shishido F, Ogawa T, Uemura K. Positron emission tomographic evaluation of histological malignancy in gliomas using oxygen-15 and fluorine-18-fluorodeoxyglucose. Neurol Res 1986: 8 (3): 164-168.
9. 82Rb PET. J Comput Assist Tomogr 1987; 11: 563-570.
10. Heiss WD, Wienhard K, Wagner R, Lanfermann H, Thiel A, Herholz K et al. F-Dopa as an amino acid tracer to detect brain tumors. J Nucl Med 1996; 37 (7): 1180-1182.
11. Price P, Newell DR, Connors T, Harte R, Wells P, Brock C et al. The potential of tracer kinetic studies in drug development programs: a new investigational area for cancer research (meeting abstract). Ann Oncol 1996; 7 (Supl 1): 24.
12. Buchpiguel CA, Alavi JB, Alavi A, Kenyon LC. PET versus SPECT in distinguishing radiation necrosis from tumor recurrence in the brain. J Nucl Med 1995; 36: 159-164.
13. Sasaki NI, Kuwabara Y, Yoshida T, Nakagawa M, Fu-kuumura T, Futoshi M et al. A comparative study of tha-llium-201 SPET, carbon-11 methionine PET and fluori-ne-18-fluorodeoxyglucose PET for the differentiation of astrocytic tumors. Eur J Nucl Med 1998; 25: 1261-1269.
14. Weber W, Bartenstein P, Gross MW, Kinzel D, Daschner H, Feldmann HJ et al. Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors. J Nucl Med 1997; 38 (5): 802-808.
15. Hawkins RA, Hoh CK. PET FDG studies in oncology. Nucl Med and Biol 1994; 21: 739-747.
16. Hoh CK, Schiepers C, Seltzer MA et al. PET in oncology: will it replace the other modalities? Sem Nucl Med 1997; 27: 94-106.
17. Warburg O. The metabolism of tumors. Nueva York: Richard R. Smith, 1931; 129-169.
18. Warburg O. On the origins of cancer cells. Science 1956; 123: 309-314.
19. 18F]-FDG in oncology: a clinical update. Nucl Med and Biol 1996; 23: 717-735.
20. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem et al. Oncological applications of positron emission tomography with fluorine-18-fluorodeoxyglucose. Eur J Nucl Med 1996; 23: 1641-1674.
21. Brock CS, Meikle SR, Price P. Does F-18 fluorodeoxyglu-cose metabolic imaging of tumors benefit oncology? Eur J Nucl Med 1997; 24: 691-705.
22. 18F]- fluorodeoxyglucose in brain tumors-a powerful diagnostic and prognostic tool. Invest Radiol 1987; 22: 360-371.
23. 18F-FDG uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 1995; 195: 47-52.
24. Schifter T, Hoffman JM, Hanson MW, Boyko OK, Beam C, Paine S et al. Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors. J Comput Assist Tomogr 1993; 17 (4): 509-561.
25. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative rate of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated Thy-midine uptake. J Nucl Med 1993; 34: 414-419.
26. Fulham MJ, Melisi JW, Nishimiya J, Dwyer AJ, Di Chiro G. Neuroimaging of juvenile pilocytic astrocytomas: an enigma. Radiology 1993; 189 (1): 221-225.
27. Patronas NJ, Di Chiro G, Smith RH, De la Paz R, Brooks RA, Milam HL et al. Depressed cerebellar glucose metabolism in supratentorial tumors. Brain Res 1984; 291 (1): 93-101.
28. 18F]FDG in brain abscess: a PET study. J Comput Assist Tomogr 1990; 14 (3): 486-487.
29. 11C-methionine and fluorine-18 FDG PET study in brain hematoma. J Nucl Med 1994; 35: 1162-1166.
30. 18F-fluoro-deoxy-glucose in vivo: high accumulation in macrophages and granulation tissues studied by micro-autoradiography. J Nucl Med 1992; 33: 1972-1980.
31. Herholz K, Holzer T, Bauer B, Schroder R, Voges J, Ernestus RI et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998; 50 (5): 1316-1322.
32. Meyer GJ, Schober O, Hundeshagen H. Uptake of 11C-L-and D-methionine in brain tumors. Eur J Nucl Med 1985; 10 (7-8): 373-376.
33. Bergstrom M, Lundquist H, Ericson K, Lilja A, Johns-trom P, Langstrom B et al. Comparison of the accumulation kinetics of L-(methyl-11C)-methionine and D-(methyl-11C)-methionine in brain tumors studied with positron emission tomography. Acta Radiol 1987; 28 (3): 225-229.
34. Kubota K, Yamada K, Fukada H, Endo S, Ito M, Abe Y et al. Tumor detection with carbon-11-labeled amino acids. Eur J Nucl Med 1984; 9 (3): 136-140.
35. Shields AF, Lim K, Grierson J, Link J, Krohn KA. Utilization of labeled thymidine in DNA synthesis: studies for PET. J Nucl Med 1990; 31 (3): 337-342.
36. Vander-Borght T, Pauwels S, Lambotte L, Labar D, De-Maeght S, Stroobandt G et al. Brain tumor imaging with PET and 2-[carbon-11]thymidine. J Nucl Med 1994; 35 (6): 974-982.
37. Ito M, Lammertsma AA, Wise RJ, Bernardi S, Fracko-wiak RS, Heather JD et al. Measurement of regional cerebral blood flow and oxygen utilization in patients with cerebral tumors using 15O and positron emission tomography: analytical techniques and preliminary results. Neuroradiology 1982; 23: 63-74.
38. Thiel A, Herholz K, Von-Stockhausen HM, Van-Leyen-Pilgram K, Piertzyk U, Kessler J et al. Localization of language-related cortex with 15O-labeled water PET in patients with gliomas. Neuroimage 1998; 7 (4 Pt 1): 284-295.
39. Andrich MP, Neumann R. The role of PET imaging in early assessment of the anti-tumor impact of biolo-gics and cytotoxics. Curr Opinion Oncol 1994; 6: 627-637.
40. Brock CS, Matthews JC, Brown G, Osman S, Luthra SK, Brady-F-Newlands ES et al. Temozolomide uptake in human astrocytomas demonstrated in vivo (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1997; 16: 812.
41. 18F]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993; 189: 847-850.
42. Kim CK, Gupta NC, Chandramouli B, Alvi A. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. J Nucl Med 1994; 35: 164-167.
43. Di Chiro G, Brooks RA. PET quantitation: blessing and curse [editorial]. J Nucl Med 1988; 29: 1603-1604.
44. Schmidt KC, Lucignani G, Sokoloff L. Fluorine-18-fluo-ro-deoxyglucose utilization: a reexamination. J Nucl Med 1996; 37: 394-399.
45. Ishizu K, Nishizawa S, Yonekura Y, Sadato N, Magata Y, Tamaki N et al. Effects of hyperglycemia on FDG uptake in human brain and glioma. J Nucl Med 1994; 35: 1104-1109.
46. Coleman RE, Hoffman JM, Hanson MW, Sostman HD, Schold SC. Clinical application of PET for the evaluation of brain tumors. J Nucl Med 1991; 32: 616-622.
47. Alavi JB, Alavi A, Chawluk et al. Positron Emission Tomography in patients with glioma: a predictor of prognosis. Cancer 1988; 62: 1074-1078.
48. Ishii K, Ogawa T, Hatazawa J, Kanno I, Inugami A, Fuji-ta H et al. High L-methyl-[11C]methionine uptake in brain abscess: a PET study. J Comput Assist Tomogr 1993; 17 (4): 660-661.
49. Pirotte B, Goldman S, Bidaut LM, Luxen A, Stanus E, Brucher JM et al. Use of positron emission tomography (PET) in stereotactic conditions for brain biopsy. Acta Neurochir Wien 1995; 134 (1-2): 79-82.
50. Levivier M, Goldman S, Bidaut LM, Luxen A, Stanus E, Przedborski S et al. Positron emission tomography-guided stereotactic brain biopsy. Neurosurgery 1992; 31 (4): 792-797 [discussion 797].
51. Francavilla TL, Miletich RS, Di Chiro G, Patronas NJ, Rizzoli HV, Wright DC. Positron emission tomography in detection of malignant degeneration of low-grade gliomas. Neurosurgery 1989; 24 (1): 1-5.
52. Janus TJ, Kim EE, Tilbury R, Bruner JM, Yung WK. Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 1993; 33: 540-548.
53. Bergstrom M, Collins VP, Ehrin E, Ericson K, Eriksson L, Greitz T et al. Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga] EDTA, [11C] glucose, and [11C]methionine. J Comput Assist Tomogr 1983; 7 (6): 1062-1066.
54. Kaschten B, Sadzot B, Stevenaert A. Evaluation of brain tumor metabolism by PET. J Neurooncol 1994; 21: 2.
55. Ogawa T, Inugami A, Hatazawa J, Kanno I, Murakami M, Yasui N et al. Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F18 and L-methyl-11C-methionine. Am J Neuroradiol 1996; 17 (2): 345-353.
56. Kaschten B, Stevenaert A, Sadzot B, Deprez M, Deguel-dre C, Del Fiore G. Preoperative evaluation of 54 glio-mas by PET with Fluorine-18- fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998; 39: 778-785.
57. Husband JE. Imaging of treated cancer. Brit J Radiol 1995; 68: 1-12.
58. Husband JE. Monitoring tumour response. European Radiology 1996; 6: 775-785.
59. Glantz MJ, Hoffman JM, Coleman RE, Friedman AH, Hanson MW, Burger PC et al. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography [see comments]. Ann Neurol 1991; 29 (4): 347-355.
60. Comment in: Ann Neurol 1991; 29 (4): 345-346.
61. Fulham MJ, Brunetti A, Aloj L, Raman R, Dwyer Al, Di Chiro G et al. Decreased cerebral glucose metabolism in patients with brain tumors: an effect of corticosteroids. J Neurosurg 1995; 83: 657-664.
62. Roelcke U, Blasberg RG, Von Ammon K, Hofer S, Vonto-bel P, Maguire RP et al. Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluoro-deoxyglucose uptake measurements in gliomas. J Nucl Med 1998; 39: 879-884.
63. Theodore WH, Di Chiro G, Margolin R, Fishbein D, Porter RJ, Brooks RA. Barbiturates reduce human cerebral glucose metabolism. Neurology 1986; 36: 60-64.
64. Phillips PC, Dhawan V, Strother SC, Sidtis JJ, Evans AC, Allen JC et al. Reduced cerebral glucose metabolism and increased brain capillary permeability following high-dose methotrexate chemotherapy: a positron emission tomographic study. Ann Neurol 1987; 21 (1): 59-63.
65. Ito M, Patronas NJ, Di Chiro G, Mansi L, Kennedy C. Effect of moderate level x-radiation to brain on cerebral glucose utilization. J Comput Assist Tomogr 1986, 10 (4): 584-588.
66. Wang GJ, Volkow ND, Lau YH, Fowler JS, Meek AG, Park TL et al. Glucose metabolic changes in nontumoral brain tissue of patients with brain tumor following radiotherapy: a preliminary study. J Comput Assist Tomogr 1996; 20 (5): 709-714.
67. Hölzer T, Herholtz K, Jeske J, Heiss WD. FDG-PET as a prognostic indicator in radiochemotherapy of glioblasto-ma. J Comput Assist Tomogr 1993; 17: 681-687.
68. Ishikawa M, Kikuchi H, Miyatake S, Oda Y, Yonekura Y, Nishizawa S. Glucose consumption in recurrent glio-mas. Neurosurgery 1993; 33 (1): 28-33.
69. Di Chiro G, Oldfield E, Wright DC, De Michele D, Katz DA, Patronas NJ et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. Am J Roent-genol 1988; 150 (1): 189-197.
70. Patronas NJ, Di Chiro G, Kufta C, Bairamian D, Korn-blith PL, Simon R et al. Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 1986; 62 (6): 816-822.
71. Ogawa T, Kanno I, Shishido F, Inugami A, Higano S, Fujita H et al. Clinical value of PET with 18F-fluorode-oxyglucose and L-methyl-11C-methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol 1991; 32 (3): 197-202.
72. 11C-metionina al estudio PET con 18FDG en los tumores cerebrales. Revista Española de Medicina Nuclear 1998; 17 (3): 205.
73. Sasaki M, Ichiya Y, Kuwabara Y, Otsuka M, Tahara T, Fukumura T et al. Ringlike uptake of [18F]FDG in brain abscess: a PET study. J Comput Assist Tomogr 1990; 14 (3): 486-487.